FDA to Liberalize Obesity Drug Process

October 11th, 2012 by MorganDowney Leave a reply »

The Food and Drug Administration  (FDA) may have gotten the word. A report on Bloomberg Businessweek indicates the FDA is considering, for obesity and infectious disease treatments, allowing developers to conduct faster clinical trials with a small group of patients than now required. The proposal evidently would look at a pathway to ensure that the drugs were only used in patients where there was an applicable risk-benefit situation. Bloomberg Businessweek: Faster Process for Obesity Drugs

To my mind, this is the kind of policy which could energize drug developer to start (or restart) obesity drug development programs. “High time”, in my view.

Leave a Reply